See more : First Citizens BancShares, Inc. (FCNCA) Income Statement Analysis – Financial Results
Complete financial analysis of VectivBio Holding AG (VECT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VectivBio Holding AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Candles Scandinavia AB (publ) (CANDLE-B.ST) Income Statement Analysis – Financial Results
- Anhui Shiny Electronic Technology Company Limited (300956.SZ) Income Statement Analysis – Financial Results
- Cypress Technology Co.,Ltd. (3541.TWO) Income Statement Analysis – Financial Results
- Pro-Ship Incorporated (3763.T) Income Statement Analysis – Financial Results
- Summit Securities Limited (SUMMITSEC.BO) Income Statement Analysis – Financial Results
VectivBio Holding AG (VECT)
About VectivBio Holding AG
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 27.34M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 27.34M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.95M | 50.18M | 43.04M | 15.98M |
| General & Administrative | 33.91M | 35.81M | 14.02M | 8.23M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.91M | 35.81M | 14.02M | 8.23M |
| Other Expenses | 0.00 | 729.00K | 207.00K | 102.00K |
| Operating Expenses | 107.87M | 86.72M | 57.26M | 24.32M |
| Cost & Expenses | 107.87M | 86.72M | 57.26M | 24.32M |
| Interest Income | 676.00K | 0.00 | 1.00K | 15.00K |
| Interest Expense | 3.16M | 36.00K | 554.00K | 50.00K |
| Depreciation & Amortization | 676.00K | 303.00K | -293.00K | 167.00K |
| EBITDA | -79.85M | -86.41M | -57.55M | -24.15M |
| EBITDA Ratio | -292.04% | 0.00% | 0.00% | 0.00% |
| Operating Income | -80.52M | -86.72M | -57.26M | -24.32M |
| Operating Income Ratio | -294.52% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.10M | -293.00K | -2.68M | 834.00K |
| Income Before Tax | -93.63M | -86.95M | -59.94M | -23.48M |
| Income Before Tax Ratio | -342.45% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 107.00K | 64.00K | 554.00K | 50.00K |
| Net Income | -93.74M | -87.01M | -60.50M | -23.53M |
| Net Income Ratio | -342.84% | 0.00% | 0.00% | 0.00% |
| EPS | -2.12 | -3.23 | -6.30 | -1.01 |
| EPS Diluted | -2.12 | -3.23 | -6.30 | -1.01 |
| Weighted Avg Shares Out | 44.13M | 26.96M | 9.60M | 23.35M |
| Weighted Avg Shares Out (Dil) | 44.13M | 26.96M | 9.60M | 23.35M |
US IPO Weekly Recap: The IPO Market Cools Off In A 2 IPO Week
Two Biotechs Are Set to Start Trading Today
Source: https://incomestatements.info
Category: Stock Reports